| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 75 | 2023 | 1242 | 8.230 |
Why?
|
| Magnetic Resonance Imaging | 66 | 2023 | 878 | 6.100 |
Why?
|
| Brain Mapping | 27 | 2022 | 124 | 4.810 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 18 | 2022 | 88 | 4.160 |
Why?
|
| White Matter | 21 | 2023 | 113 | 4.020 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 806 | 3.720 |
Why?
|
| Image Processing, Computer-Assisted | 19 | 2023 | 139 | 3.670 |
Why?
|
| Alzheimer Disease | 38 | 2023 | 1415 | 3.570 |
Why?
|
| Aging | 33 | 2023 | 1180 | 2.820 |
Why?
|
| Diffusion Tensor Imaging | 11 | 2023 | 49 | 2.710 |
Why?
|
| Image Interpretation, Computer-Assisted | 10 | 2017 | 59 | 2.220 |
Why?
|
| Cognition | 28 | 2023 | 1026 | 2.190 |
Why?
|
| Aged | 67 | 2023 | 7667 | 1.900 |
Why?
|
| Aged, 80 and over | 57 | 2023 | 3866 | 1.890 |
Why?
|
| Nervous System Diseases | 3 | 2022 | 101 | 1.820 |
Why?
|
| Humans | 124 | 2023 | 23235 | 1.820 |
Why?
|
| Neuroimaging | 12 | 2023 | 105 | 1.640 |
Why?
|
| Hippocampus | 14 | 2022 | 200 | 1.520 |
Why?
|
| Male | 75 | 2023 | 12673 | 1.430 |
Why?
|
| Female | 73 | 2023 | 13159 | 1.400 |
Why?
|
| Neural Pathways | 11 | 2020 | 54 | 1.340 |
Why?
|
| TDP-43 Proteinopathies | 6 | 2022 | 87 | 1.280 |
Why?
|
| Algorithms | 10 | 2014 | 305 | 1.250 |
Why?
|
| Image Enhancement | 8 | 2013 | 42 | 1.240 |
Why?
|
| Cerebral Amyloid Angiopathy | 5 | 2023 | 96 | 1.100 |
Why?
|
| Artifacts | 11 | 2023 | 29 | 1.090 |
Why?
|
| DNA-Binding Proteins | 7 | 2022 | 231 | 1.070 |
Why?
|
| Arteriolosclerosis | 4 | 2023 | 61 | 1.070 |
Why?
|
| Organ Size | 10 | 2019 | 87 | 0.980 |
Why?
|
| Independent Living | 6 | 2022 | 240 | 0.970 |
Why?
|
| Cohort Studies | 21 | 2023 | 1467 | 0.920 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2016 | 152 | 0.870 |
Why?
|
| Neuropsychological Tests | 18 | 2022 | 917 | 0.770 |
Why?
|
| Gray Matter | 7 | 2020 | 43 | 0.760 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2011 | 25 | 0.720 |
Why?
|
| Overweight | 1 | 2021 | 66 | 0.670 |
Why?
|
| Reproducibility of Results | 10 | 2023 | 599 | 0.660 |
Why?
|
| Connectome | 1 | 2020 | 11 | 0.650 |
Why?
|
| Adult | 24 | 2023 | 6972 | 0.650 |
Why?
|
| Cerebrovascular Disorders | 4 | 2022 | 104 | 0.640 |
Why?
|
| Cognitive Aging | 2 | 2021 | 64 | 0.620 |
Why?
|
| Cerebral Cortex | 5 | 2022 | 132 | 0.620 |
Why?
|
| Cerebrovascular Circulation | 4 | 2022 | 28 | 0.610 |
Why?
|
| Cognition Disorders | 9 | 2023 | 726 | 0.600 |
Why?
|
| Anisotropy | 10 | 2023 | 36 | 0.590 |
Why?
|
| Amygdala | 1 | 2019 | 35 | 0.570 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 1106 | 0.550 |
Why?
|
| Autopsy | 9 | 2021 | 260 | 0.530 |
Why?
|
| Cerebral Small Vessel Diseases | 3 | 2022 | 10 | 0.520 |
Why?
|
| Genome-Wide Association Study | 8 | 2019 | 160 | 0.520 |
Why?
|
| Frontal Lobe | 4 | 2019 | 57 | 0.510 |
Why?
|
| Young Adult | 8 | 2020 | 1659 | 0.500 |
Why?
|
| Atrophy | 4 | 2021 | 68 | 0.450 |
Why?
|
| Sensitivity and Specificity | 9 | 2023 | 446 | 0.440 |
Why?
|
| Dementia | 5 | 2023 | 416 | 0.420 |
Why?
|
| Cerebral Infarction | 4 | 2020 | 113 | 0.420 |
Why?
|
| Postmortem Changes | 2 | 2016 | 22 | 0.410 |
Why?
|
| Nerve Fibers | 3 | 2014 | 10 | 0.400 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 9 | 0.400 |
Why?
|
| Neurodegenerative Diseases | 3 | 2021 | 98 | 0.360 |
Why?
|
| Memory | 6 | 2021 | 225 | 0.360 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 72 | 0.340 |
Why?
|
| Reference Values | 6 | 2013 | 169 | 0.330 |
Why?
|
| Genetic Variation | 3 | 2019 | 72 | 0.330 |
Why?
|
| Models, Anatomic | 1 | 2010 | 34 | 0.320 |
Why?
|
| Fourier Analysis | 1 | 2010 | 7 | 0.320 |
Why?
|
| Biomarkers | 7 | 2023 | 485 | 0.320 |
Why?
|
| Limbic System | 1 | 2009 | 7 | 0.300 |
Why?
|
| Formaldehyde | 1 | 2009 | 7 | 0.300 |
Why?
|
| Phobic Disorders | 1 | 2009 | 65 | 0.290 |
Why?
|
| Temporal Lobe | 5 | 2020 | 58 | 0.290 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2020 | 41 | 0.280 |
Why?
|
| Information Storage and Retrieval | 1 | 2008 | 2 | 0.280 |
Why?
|
| Pulse | 1 | 2008 | 3 | 0.280 |
Why?
|
| Myocardial Contraction | 1 | 2008 | 37 | 0.270 |
Why?
|
| Atlases as Topic | 2 | 2020 | 6 | 0.270 |
Why?
|
| Brain Neoplasms | 2 | 2006 | 73 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 176 | 0.260 |
Why?
|
| Neuropathology | 4 | 2021 | 63 | 0.260 |
Why?
|
| Exercise | 2 | 2021 | 404 | 0.250 |
Why?
|
| Middle Aged | 14 | 2021 | 7986 | 0.240 |
Why?
|
| Antibodies, Antiphospholipid | 2 | 2019 | 20 | 0.240 |
Why?
|
| Diffuse Axonal Injury | 2 | 2004 | 2 | 0.240 |
Why?
|
| Genetic Loci | 4 | 2019 | 31 | 0.230 |
Why?
|
| Positron-Emission Tomography | 2 | 2023 | 75 | 0.230 |
Why?
|
| Axons | 2 | 2004 | 24 | 0.230 |
Why?
|
| Cerebral Hemorrhage | 2 | 2023 | 104 | 0.230 |
Why?
|
| Frontotemporal Dementia | 2 | 2022 | 11 | 0.230 |
Why?
|
| Linear Models | 5 | 2019 | 202 | 0.230 |
Why?
|
| Memory, Episodic | 2 | 2019 | 81 | 0.220 |
Why?
|
| tau Proteins | 3 | 2023 | 153 | 0.220 |
Why?
|
| Prefrontal Cortex | 3 | 2016 | 107 | 0.220 |
Why?
|
| Amyloid beta-Peptides | 3 | 2023 | 210 | 0.220 |
Why?
|
| Neuropeptides | 3 | 2020 | 22 | 0.210 |
Why?
|
| Tauopathies | 1 | 2023 | 14 | 0.200 |
Why?
|
| Brain Diseases | 2 | 2021 | 57 | 0.200 |
Why?
|
| Lewy Bodies | 2 | 2021 | 151 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 779 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 117 | 0.190 |
Why?
|
| Phantoms, Imaging | 4 | 2010 | 33 | 0.190 |
Why?
|
| Dementia, Vascular | 1 | 2023 | 36 | 0.190 |
Why?
|
| DNA Methylation | 3 | 2019 | 129 | 0.190 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2022 | 21 | 0.190 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2002 | 21 | 0.190 |
Why?
|
| Health Literacy | 1 | 2023 | 87 | 0.180 |
Why?
|
| Inflammation | 2 | 2016 | 231 | 0.180 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 7 | 0.170 |
Why?
|
| Proteomics | 1 | 2022 | 61 | 0.170 |
Why?
|
| Disease Progression | 2 | 2021 | 547 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2021 | 55 | 0.170 |
Why?
|
| Vitamin D | 1 | 2021 | 28 | 0.170 |
Why?
|
| Psychomotor Performance | 3 | 2020 | 165 | 0.170 |
Why?
|
| Stroke | 2 | 2016 | 243 | 0.170 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 26 | 0.160 |
Why?
|
| Gene Expression | 2 | 2019 | 180 | 0.160 |
Why?
|
| Hypertension | 1 | 2022 | 169 | 0.160 |
Why?
|
| Proteins | 1 | 2020 | 52 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 296 | 0.160 |
Why?
|
| Neurologic Examination | 1 | 2020 | 82 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 47 | 0.160 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 3 | 0.160 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 9 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 168 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 44 | 0.150 |
Why?
|
| Occipital Lobe | 1 | 2019 | 4 | 0.150 |
Why?
|
| Motor Skills | 2 | 2021 | 38 | 0.150 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 5 | 0.150 |
Why?
|
| Age Factors | 3 | 2016 | 651 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 6 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2019 | 14 | 0.150 |
Why?
|
| Parietal Lobe | 1 | 2019 | 12 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 17 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 35 | 0.150 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 9 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 21 | 0.150 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 58 | 0.150 |
Why?
|
| Parkinsonian Disorders | 1 | 2021 | 170 | 0.150 |
Why?
|
| Transcriptome | 1 | 2019 | 54 | 0.150 |
Why?
|
| Motor Disorders | 1 | 2019 | 18 | 0.150 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2019 | 22 | 0.150 |
Why?
|
| Lateral Ventricles | 1 | 2018 | 4 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 277 | 0.140 |
Why?
|
| Olfaction Disorders | 1 | 2019 | 38 | 0.140 |
Why?
|
| Genome, Human | 1 | 2018 | 34 | 0.140 |
Why?
|
| Kidney | 1 | 2019 | 142 | 0.140 |
Why?
|
| Health Behavior | 1 | 2019 | 140 | 0.140 |
Why?
|
| Adolescent | 3 | 2018 | 1884 | 0.140 |
Why?
|
| Delay Discounting | 1 | 2018 | 20 | 0.140 |
Why?
|
| Datasets as Topic | 1 | 2018 | 2 | 0.140 |
Why?
|
| Brain Infarction | 1 | 2017 | 63 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 20 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 30 | 0.130 |
Why?
|
| Neurons | 1 | 2019 | 273 | 0.130 |
Why?
|
| Time Factors | 5 | 2019 | 1265 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 283 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 73 | 0.120 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2016 | 2 | 0.120 |
Why?
|
| Perforant Pathway | 1 | 2016 | 4 | 0.120 |
Why?
|
| Computer Simulation | 2 | 2008 | 173 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2017 | 140 | 0.120 |
Why?
|
| Intelligence | 1 | 2016 | 14 | 0.120 |
Why?
|
| Economics | 1 | 2016 | 13 | 0.120 |
Why?
|
| Neocortex | 1 | 2016 | 23 | 0.120 |
Why?
|
| Comprehension | 1 | 2016 | 25 | 0.120 |
Why?
|
| Pyramidal Tracts | 2 | 2014 | 3 | 0.120 |
Why?
|
| Corpus Callosum | 2 | 2014 | 10 | 0.120 |
Why?
|
| Sleep Deprivation | 1 | 2016 | 35 | 0.120 |
Why?
|
| Dominance, Cerebral | 2 | 2013 | 14 | 0.110 |
Why?
|
| Evoked Potentials | 2 | 2007 | 11 | 0.110 |
Why?
|
| Microglia | 1 | 2016 | 108 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2009 | 486 | 0.110 |
Why?
|
| Gyrus Cinguli | 1 | 2014 | 13 | 0.110 |
Why?
|
| Risk Factors | 4 | 2022 | 2022 | 0.100 |
Why?
|
| Financial Management | 1 | 2014 | 18 | 0.100 |
Why?
|
| Nerve Net | 3 | 2019 | 34 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 34 | 0.100 |
Why?
|
| Reward | 1 | 2013 | 18 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2016 | 273 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2013 | 40 | 0.100 |
Why?
|
| Motor Activity | 1 | 2015 | 274 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 153 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 13 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 19 | 0.090 |
Why?
|
| United States | 2 | 2021 | 1805 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2014 | 310 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 2 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2012 | 27 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2012 | 57 | 0.090 |
Why?
|
| Diffusion | 2 | 2002 | 24 | 0.090 |
Why?
|
| Cadaver | 1 | 2013 | 285 | 0.090 |
Why?
|
| Risk-Taking | 1 | 2011 | 28 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2012 | 127 | 0.080 |
Why?
|
| Motion | 1 | 2009 | 20 | 0.080 |
Why?
|
| Fixatives | 1 | 2009 | 5 | 0.070 |
Why?
|
| Sclerosis | 2 | 2019 | 54 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2019 | 15 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1512 | 0.070 |
Why?
|
| Self Report | 2 | 2021 | 202 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 521 | 0.070 |
Why?
|
| Genotype | 2 | 2019 | 265 | 0.070 |
Why?
|
| Probability | 2 | 2021 | 72 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 260 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2006 | 77 | 0.060 |
Why?
|
| Software | 1 | 2005 | 50 | 0.060 |
Why?
|
| Alleles | 2 | 2017 | 172 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2006 | 107 | 0.060 |
Why?
|
| Actigraphy | 2 | 2016 | 81 | 0.060 |
Why?
|
| Reaction Time | 2 | 2021 | 81 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2006 | 116 | 0.050 |
Why?
|
| Motor Cortex | 2 | 2002 | 16 | 0.050 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2004 | 7 | 0.050 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 8 | 0.050 |
Why?
|
| Caloric Restriction | 1 | 2023 | 12 | 0.050 |
Why?
|
| Brain Edema | 1 | 2003 | 16 | 0.050 |
Why?
|
| Depression | 2 | 2017 | 383 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2003 | 31 | 0.050 |
Why?
|
| Acculturation | 1 | 2023 | 25 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 54 | 0.050 |
Why?
|
| Oligodendroglioma | 1 | 2002 | 4 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 59 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 94 | 0.050 |
Why?
|
| Nonlinear Dynamics | 1 | 2002 | 11 | 0.050 |
Why?
|
| Age of Onset | 1 | 2002 | 74 | 0.050 |
Why?
|
| Biological Clocks | 1 | 2002 | 11 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 83 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2022 | 74 | 0.050 |
Why?
|
| Internal Capsule | 1 | 2002 | 1 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 19 | 0.040 |
Why?
|
| Oxygen | 2 | 2011 | 57 | 0.040 |
Why?
|
| Arousal | 1 | 2001 | 48 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 13 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 94 | 0.040 |
Why?
|
| ROC Curve | 2 | 2016 | 122 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 171 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 25 | 0.040 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 4 | 0.040 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 8 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 8 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 16 | 0.040 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 8 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 76 | 0.040 |
Why?
|
| Visual Cortex | 1 | 2000 | 4 | 0.040 |
Why?
|
| Auditory Cortex | 1 | 2000 | 3 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 12 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2000 | 19 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 43 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2000 | 54 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 46 | 0.040 |
Why?
|
| Research | 1 | 2000 | 36 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 35 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 162 | 0.040 |
Why?
|
| Heredity | 1 | 2019 | 6 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 40 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2019 | 36 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 2 | 0.040 |
Why?
|
| Nestin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2019 | 9 | 0.040 |
Why?
|
| Neurogenesis | 1 | 2019 | 7 | 0.040 |
Why?
|
| SNARE Proteins | 1 | 2019 | 9 | 0.040 |
Why?
|
| Accelerometry | 1 | 2019 | 83 | 0.040 |
Why?
|
| Entorhinal Cortex | 1 | 2019 | 21 | 0.040 |
Why?
|
| Diagnosis | 1 | 2018 | 18 | 0.040 |
Why?
|
| Chicago | 1 | 2021 | 848 | 0.040 |
Why?
|
| Demography | 1 | 2018 | 60 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 2002 | 355 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 463 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 25 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 35 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2011 | 85 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2017 | 4 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 26 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 29 | 0.030 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Methionine Sulfoxide Reductases | 1 | 2017 | 4 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 8 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2017 | 41 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 60 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 3305 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 314 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 40 | 0.030 |
Why?
|
| Borderline Personality Disorder | 1 | 2016 | 3 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 17 | 0.030 |
Why?
|
| Personality | 1 | 2016 | 42 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 10 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 104 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1431 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 31 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Decision Making | 1 | 2016 | 179 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 166 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 357 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 160 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 29 | 0.030 |
Why?
|
| Sleep | 1 | 2016 | 270 | 0.020 |
Why?
|
| Child | 1 | 2017 | 1161 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 17 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 23 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 30 | 0.020 |
Why?
|
| Games, Experimental | 1 | 2011 | 6 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2011 | 73 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 2994 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2016 | 595 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 19 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2004 | 4 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 2004 | 7 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2004 | 12 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 28 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2002 | 15 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2002 | 9 | 0.010 |
Why?
|
| Fingers | 1 | 2002 | 8 | 0.010 |
Why?
|
| Rotation | 1 | 2002 | 109 | 0.010 |
Why?
|
| Evoked Potentials, Motor | 1 | 2002 | 9 | 0.010 |
Why?
|
| Echo-Planar Imaging | 1 | 2002 | 4 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 39 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 63 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2002 | 54 | 0.010 |
Why?
|
| Intervertebral Disc | 1 | 2002 | 114 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 485 | 0.010 |
Why?
|
| Spine | 1 | 2002 | 98 | 0.010 |
Why?
|
| Movement | 1 | 2002 | 106 | 0.010 |
Why?
|
| Rest | 1 | 2001 | 28 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 135 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 538 | 0.010 |
Why?
|
| Mental Processes | 1 | 2000 | 15 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 578 | 0.010 |
Why?
|